{"id":1017929,"date":"2026-11-05T18:28:50","date_gmt":"2026-11-05T23:28:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/health-catalyst-reports-third-quarter-2026-results\/"},"modified":"2026-11-05T18:28:50","modified_gmt":"2026-11-05T23:28:50","slug":"health-catalyst-reports-third-quarter-2026-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/health-catalyst-reports-third-quarter-2026-results\/","title":{"rendered":"Health Catalyst Reports Third Quarter 2026 Results"},"content":{"rendered":"
\n

SALT LAKE CITY, Nov. 05, 2026 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (\u201cHealth Catalyst,\u201d Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended September 30, 2026.<\/p>\n

\u201cWe delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook,\u201d said Simeon Kohl, President and Chief Executive Officer of Health Catalyst. \u201cOur immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue.\u201d<\/p>\n

\n Financial Highlights for the <\/strong>
\n Three Months Ended September 30, 2026<\/strong>\n <\/p>\n

\n
\n Key Financial Metrics<\/em>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\n Three Months Ended September 30,<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Year over Year
Change<\/strong>
\n \n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\n 2026<\/strong>
\n
\n (2)<\/strong>
\n <\/sup>\n <\/td>\n		\u00a0<\/td>\n\n 2025<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n<\/tr>\n
\n GAAP Financial Measures:<\/strong>\n <\/td>\n\n (in thousands, except percentages, unaudited)<\/strong>\n <\/td>\n<\/tr>\n
Total revenue\u00a0<\/td>\n$<\/td>\n56,283<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n76,323<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(26<\/td>\n)%<\/td>\n<\/tr>\n
Gross profit\u00a0<\/td>\n$<\/td>\n17,345<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n29,979<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(42<\/td>\n)%<\/td>\n<\/tr>\n
Gross margin\u00a0<\/td>\n\u00a0<\/td>\n31<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n39<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net income (loss)\u00a0<\/td>\n$<\/td>\n40,496<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n(22,229<\/td>\n)<\/td>\n\u00a0<\/td>\n282<\/td>\n%<\/td>\n<\/tr>\n
\n Non-GAAP Financial Measures:<\/strong>
\n
\n (1)<\/strong>
\n <\/sup>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted Gross Profit\u00a0<\/td>\n$<\/td>\n24,913<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n40,133<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(38<\/td>\n)%<\/td>\n<\/tr>\n
Adjusted Gross Margin\u00a0<\/td>\n\u00a0<\/td>\n44<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n53<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted EBITDA\u00a0<\/td>\n$<\/td>\n779<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n12,000<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(94<\/td>\n)%<\/td>\n<\/tr>\n<\/table>\n

________________________<\/p>\n\n\n\n\n\n
\n (1) <\/sup>\n <\/td>\n\n These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying “Non-GAAP Financial Measures” section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.<\/sup>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n (2)<\/sup>\n <\/td>\n\n The net income generated during the three months ended September 30, 2026 was largely driven by a $65.9 million gain on sale of the Vitalware Business, while total revenue, gross profit, gross margin, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted EBITDA decreased year-over-year primarily as a result of the divestiture of the Vitalware Business on July 31, 2026 and headwinds related to the migration from DOS to Ignite, partially offset by our cost reduction initiatives. See Management’s Discussion and Analysis of Financial Condition and Results of Operations for more detail.<\/sup>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Financial Outlook<\/strong>\n <\/p>\n

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.<\/p>\n

For the full year of 2026, we expect:<\/p>\n